Susan Hubbard
EVP of Public Affairs and Investor Relations
Replay available
Exelixis (NASDAQ:EXEL) Q1 2020 earnings call, held 2020-05-05. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/exelixis-inc-exel-q1-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good afternoon, ladies and gentlemen, and welcome to the Exalysis First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. If you should require assistance during the conference, please press star then the zero on your touchtone telephone. As a reminder, this conference is being recorded I would now like to turn the conference over to your host, Ms. Susan Hubbard, EVP of Public Affairs and Investor Relations. Please proceed.
0:37 Thank you, Nita, and thank you all for joining us for the Exelixis First Quarter 2020 Financial Results Conference Call. Joining me on today's call are Mike Morrissey, our President and CEO, Chris Senner, our Chief Financial Officer, PJ Haley, our Executive Vice President of Commercials, and Gisa Schwab, our Chief Medical Officer. who together will review our corporate, financial, commercial, and development progress for the first quarter 2020 and in March 31, 2020. Peter Lamb, our Chief Scientific Officer, is also with us and will be joining for the Q&A session following our prepared remarks. During the call today, we will refer to financial measures not calculated according to general accepted accounting principles. Please refer to today's press release, which is posted on our website, for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results.
1:31 During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters, as well as the impact of the COVID-19 pandemic on Exalexis's business operations. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, Market Competition, Regulatory Review and Approval Processes, Conducting Clinical Trials, Compliance with Applicable Regulatory Requirements, Our Dependence on Collaboration Partners, and the Level of Costs Associated with Discovery, Product Development, Business Development, and Commercialization Activities. And now with that, I will turn it over to Mike.
2:34 All right. Thank you, Susan, and thanks to everyone for joining us on the call today. XLX has had a strong first quarter across all components of our business. Our entire team, working remotely as a cohesive unit, continues to navigate the challenges of the COVID-19 pandemic with a singular focus of ensuring that we do everything in our power to maximize access to carbamazantinib for cancer patients through either commercial channels or clinical trials. We recognize that cancer patients need to take their treatments as directed, and we've gone to great lengths to ensure patient access to our medicines in these challenging times. We'll keep our prepared remarks short and address your questions as the main part of today's update. Please see our press release that was issued an hour ago for our first quarter 2020 financial results and an extensive list of corporate highlights.
3:29 Before we review the performance of our business in the quarter, I want to provide a brief update on how Exalexis has responded to COVID-19 at an organizational level. Our top priority is the health and safety of the Exalexis workforce. So we implemented our work from home policy ahead of the California shelter in place order and quickly pivoted our sales force to move to virtual touch points with prescribers. At the same time, the 600 plus members of our XLXs team have engaged in the fight against COVID-19 on the community level by donating to charitable organizations supporting cancer patients during the pandemic, which XLXs has matched at the corporate level and through the donation of personal protective equipment We like to think that tough times brings out the best in people, and I'm proud to say that's certainly the case at XLXs.
4:23 The COVID-19 pandemic continues to evolve quickly and has had a relatively modest impact on our business to date. We remain optimistic that the 2020-2021 timeframe can be a period of focused execution and achievement for XLXs. The pandemic is imposing challenges on our day-to-day operations and gives rise to a level of uncertainty. We remain on track to have 12 label-enabling trials for COBOxantinib enrolling by year-end and achieve six top-line data readouts over the course of the year, which could lead to four new potential indications for COBO in 2021. We also expect to advance XTEL092 into immune checkpoint inhibitor or ICI combination cohorts and file up to three new INDs for compounds from internal or collaborative efforts. Obviously, everything is fluid at this stage and we'll continue to update you as we progress throughout the year.
5:22 The recent success of Checkmate 9ER with the Cabo-Nego combination and Firstline RCC highlights the important role CaboSensitive can play as a TKI backbone in driving both compelling efficacy and tolerability in ICI combination strategies and provides potential encouraging read-through for ongoing and planned pivotal trials for other ICI combinations and new indications. Finally, as you know, we have an ongoing and a litigation against MSN. Earlier today, we received notice that MSN has filed additional paragraph four certifications challenging the Cabo's Antony of the composition of matter patent and a method of use patent. Two orange book listed patents not asserted in their original paragraph four letter. We are not surprised by this development, as such challenges are standard in the ordinary course of pharmaceutical business.
6:19 We are well prepared to respond and vigorously defend what I believe to be a very strong intellectual property estate that protects Cabozantinib, an innovative drug of growing medical importance. So with that, I'll turn the call over to Gisela, who will provide an update on Checkmate 9-ER and other 2020 development activities. Isla?
6:42 Thank you, Mike. I'm very pleased to provide a brief update on our development and regulatory progress in the quarter. I'll start with a very exciting recent announcement for the Pivotal Phase III study, Checkmate 90-R, by ourselves and BMS. This important Phase III trial compares cabizantinib plus nivolumab with sunitinib in previously untreated patients with RCC, including all IMDC risk groups. The study completed enrollment earlier in 2019 and, as projected, has now achieved top-line results, as announced on April 20, 2020. We are extremely pleased with the results that showed that Checkmate 9ER met all three efficacy endpoints.
7:33 The primary endpoint was progression-free survival assessed by independent radiology committee. Carbazantinib in combination with nivolumab significantly reduced the risk of disease progression or death compared with sunitinib with a hazard ratio of 0.51 and a p-value of less than 0.0001. The secondary endpoints were overall survival and objective response rate. The combination of carbazantinib with nivolumab also significantly improved overall survival compared with asinitinib with a hazard ratio of 0.60 and a p-value equal to 0.001 and the objective response rate with a deep and durable responses observed.
8:32 The median follow-up time was 18.1 months. The preliminary analysis of the Checkmate 9ER safety data showed a favorable safety profile with the combination of a 40 milligram dose of cabozantinib combined with nivolumab with a low frequency of treatment discontinuation due to adverse events. We would like to thank the patients who participated in this trial as well as the investigators and site personnel for their perseverance during the conduct of the study and for ultimately delivering these important results for patients in the midst of the COVID-19 pandemic.
9:18 We'd also like to congratulate our collaborators at Bristol Myers Squibb who sponsored the trial and look forward to our continued collaboration with BMS as we work toward regulatory filings in the near future. We also look forward to the detailed results of Checkmate 9ER that will be submitted for presentation at an upcoming medical conference. These striking results provide further clinical support for the concept that cabozantinib may enhance the activity of immune checkpoint inhibitors. and add to the growing body of preclinical and clinical data with scientific rationale for combining cabozantinib with immune checkpoint inhibitors.
10:11 Moreover, the tolerable safety profile as seen in the preliminary analysis of safety data from CHECMED-9ER further reinforces the 40 mg cabozantinib starting dose in combination with nivolumab and it expands on similar observations in the Checkmate 040 Phase 1B trial in hepatocellular cancer presented at ASCO-GI and also our Phase 1B trial of cabozantinib and atezolizumab in COSMIC-021 Cohort 6 in prostate cancer presented at ASCO-GU this year. The scientific rationale for combining cabozantinib and checkpoint inhibitors is directly relevant for our broader ongoing and near-term planned development programs for cabozantinib across different tumor types.
11:10 This program spans 12 ongoing or near-term planned pivotal studies including our ongoing Phase III trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in first-line RCC, the COSMIC 313 trial, as well as the Phase III trial, COSMIC 312, in first-line HCC, comparing cabozantinib and atezolizumab versus serafinib. and our large multi-cohort phase 1B study evaluating the combination of cabozantinib and atezolizumab in 24 cohorts across many different tumor types and settings, as well as our near-term plan phase 3 studies in non-small cell lung cancer, CRPC and renal cell cancer under our Walsh 50-50 clinical collaboration agreement.
12:16 This broad, late-stage carbogantinib development program is making very good progress, even in the face of the challenges that the COVID-19 pandemic presents for patients and sites, given travel restrictions and quarantine. And to close, just a few words regarding the upcoming ASCO conference. We look forward to presenting results from three cohorts of our COSMIC O2-1 study, Evaluating cabozantinib and atezolizumab in checkpoint inhibitor pretreated non-small cell lung cancer in second line bladder cancer as well as biomarker results from our cohort 6 in prostate cancer. And additional presentations including a randomized phase 2 study comparing cabozantinib and nivolumab with single agent nivolumab in endometrial cancer from the NCI CTEC program.
13:19 And with that, I will turn the call over to Chris.
13:24 Thanks, Gisela. For the first quarter of 2020, the company reported total revenues of $226.9 million. Total revenues for the quarter included Cabo's franchise net product revenues of $193.9 million. Compared to the fourth quarter of 2019, inventory of CaboMedic tell that our customer increased by approximately 500 units and inventory weeks on hand increased to approximately 2.9 weeks from 2.6 weeks and remains within the typical range of inventory weeks on hand. Total revenues also included $33 million in collaboration revenues from the company's commercial collaboration partners, Ibsen, Takeda, and Genentech. Our total operating expenses for the first quarter of 2020 were $174.1 million compared to $163 million in the fourth quarter of 2019.
14:12 R&D expense was the primary driver of the increase in total operating expenses, which increased by approximately $7 million and was primarily related to increases in clinical trial expenses as we continue to invest in maximizing the full clinical and commercial potential of Cobb Investment. Provision for income taxes for the first quarter of 2020 was $11.4 million, and our effective tax rate for the quarter was 19%, compared to $16.3 million and 19.1% for the fourth quarter of 2019. Company reported gap net income of $48.6 million, or 15 cents per share, on a fully diluted basis for the first quarter of 2020. Company also reported non-gap net income of $59.4 million, or 19 cents per share, on a fully diluted basis. Non-gap net income excludes the impact of approximately $10.8 million of stock-based compensation expense net of the related income tax effect.
15:06 Cash and investments increased by approximately $52 million during the quarter ended March 31, 2020 to over $1.4 billion. Now turning to our financial guidance. While we recognize the impact of COVID-19 pandemic is a very fluid situation, we continue to believe in the strength of our business, and therefore, we are maintaining the financial guidance we provided earlier this year. Total revenues are expected to be in the range of $850 and $900 million. Net product revenues are expected to be in the range of $725 and $775 million. Cost of goods sold is expected to be between 4% and 5% of net product revenues. Research and development expenses are expected to be in the range of $460 and $500 million and include non-cash expenses related to stock-based compensation of approximately $25 million.
15:52 Selling general administrative expenses are expected to be in the range of $230 and $250 million and include non-cash expenses related to stock-based compensation of approximately $30 million. Our guidance for the effective tax rate in 2020 is expected to be between 20% and 22%. And finally, we are projecting cash and investments to be in the range of $1.5 and $1.6 billion. This cash and investments guidance does not include the impact of any potential new business development activities. With that, I'll turn the call over to PJ.
16:22 Thank you, Chris. I'm pleased to review the commercial performance of Cabo Medics for the first quarter of 2020. Cabo Medics continues to be the number one prescribed TKI in RCC, which is notable in the context of an increasingly competitive market, which now includes three first-line immune checkpoint inhibitor, or ICI, combinations. With regards to the business, we did not see a significant impact of COVID-19 in the first quarter, as CaboMedic's weekly demand was stable in Q1 2020 relative to Q4 2019. Our team has been and continues to be focused on compliantly supporting the healthcare providers who treat COBOmedics patients since the pandemic has taken hold in the US.
17:11 We are proactively communicating the availability of drug supply to our customers, as well as supporting them by continuing to educate on the Exelixis Access Services, or EASE, program. We are doing this through virtual speaker programs, lunches, phone calls, and digital tactics. Our customers appreciate this focus on ensuring their patients have appropriate access to COBOmedics therapy in these challenging times. In Q1, the prescriber base of COBOmedics continued to grow, and COBOmedics continues to be used broadly in RCC across academic and community settings, clinical risk groups, and lines of therapy. As we have previously mentioned, the first-line RCC market stabilized in the second half of 2019, and this continued into Q1 where Cobb-O-Medic's first line new patient share remained steady and ICI combos continued to capture the majority of the first line new patient market share with approximately 75% of the market.
18:17 We are excited by the recent outcome of the Checkmate 9ER study as these results pending regulatory approval will provide us with the opportunity to grow Cobb-O-Medic's market share and increase duration of therapy As we have now been in this market for over four years, our team has deep knowledge and experience in RCC, and we would look forward to the opportunity to educate physicians on this data at the appropriate time so that more patients have the opportunity to benefit from CaboMedics therapy in the first-line setting. We are particularly pleased with the progress that CaboMedics has made in the second-line setting in Q1. where new patient market share increased to 45%.
19:02 This was driven by more ICI combination pre-treated patients progressing into the second line setting where Cabo Medix continues to be the treatment of choice for the majority of these patients, primarily due to the fact that it is the only TKI with a strong OS benefit per the label in the second line population. We are pleased to see this trend play out in the marketplace and anticipate that the strength in the second-line market will continue. Turning briefly to HCC, the U.S. Cabo Medics business remains stable. We anticipate the combination of atezolizumab and bevacizumab will receive approval in first-line HCC soon.
19:48 Subsequently, the HCC landscape will likely evolve in a similar fashion to what we saw in the RCC market with ICI combination therapy moving to the front line, which could be an important new standard of care for treatment-naive liver cancer patients and serve to expand the first-line market. We anticipate this will, in turn, increase TKI monotherapy utilization in the second-line setting as second-line ICI monotherapy use decreases over time. Additionally, we look forward to further ICI combination data with CABO and HCC to add to the Checkmate 040 data presented earlier this year.
20:34 COSMIC 312 will provide the next Phase III readout of cabozantinib in combination with an immune checkpoint inhibitor and represents another potential growth opportunity for the franchise. We strongly believe that there are many more eligible patients who could benefit from CaboMedix. CaboMedx remains the number one prescribed TKI in RCC, and we look forward to building on this momentum in RCC, HCC, and other potential future indications, such as prostate and lung, as our development program evaluating Cabozantinib in combination with immune checkpoint inhibitors expands and progresses. The exciting data from 9ER is the first of these Phase 3 combination trials to read out, and we look forward to the opportunity to bring this combination to market as we continue to build the Cabo franchise.
21:26 Our team remains highly focused and motivated to compete every day to bring the benefit of CaboMedix to all eligible patients as we continue to build the franchise and maximize its clinical and commercial potential. And with that, I will turn the call back over
21:41 to Mike. All right, PJ, thank you. As I said in the intro, we're off to a strong start in 2020. While we recognize the risk to our business should the pandemic grow in severity or continue unabated, as of now, we expect a data-rich year as we advance CAVO towards new potential indications and additional compounds into the clinic. We're excited to present new data throughout the year and specifically at the upcoming virtual ASCO meetings. Most importantly, we hope to build on the momentum from the Checkmate 9ER top-line results as we continue to chart our path to additional indications for CAVO and build out a diverse portfolio of next-generation Exalexis cancer medicines.
22:28 I'll close by thanking everyone at Exalexis for their truly Herculean efforts since early March. Our team has been working from home for almost two months now, continuing their efforts on behalf of cancer patients while also juggling the personal challenges that everyone is facing in these troubling and uncertain times. I have never been more proud or inspired by the team's resilience, focus and commitment. The entire team is dedicated to making every day count even now under such trying conditions as we discover, develop and commercialize the next generation of our medicines for cancer patients in need of better and more effective therapies. We look forward to updating you on our progress in the future. Thank you for your continued support and interest in XLXs, and we're happy to now open the call for questions.
23:17 Ladies and gentlemen, if you have a question at this time, please press star, then the number one on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. And your first question comes from the line of Astekia Goodwarden with SunTrust.
23:45 Hi, guys. This is Astekia Goodwarden from SunTrust. I find some very interesting iterations of my name on these calls. Thanks for taking the question. I want to say congrats on continuing to execute well. So with ASCO up ahead, I've got a question for Gisela here. I'm not going to ask you about the lung cancer, but you've had some more time to analyze and do some of the biomarker results for the castrate-resistant prostate cancer from cohort six. You had some time to kick this off, and Gisela, I want to know, I'm not asking what the data is, but I'd like to get your view on what you think is the most interesting translational analysis that we'll see in this data set. and then I got a couple of quick follow-ups after that.
24:36 Yeah, sure. Thank you for the question. So for the COSMiGO2-1 study, we have a pretty broad biomarker program that looks at various components of the immune cells, the tumor cells, expression patterns and genetic alterations. So a broad program and without Preempting here, as the data says, certainly looking forward to provide the information on the CRPC cohort, which we've seen already, the clinical data at ASCO-Q.
25:18 Okay. And then, so overall, you've delivered on RCC, CRPC, non-small cell, come around the corner, and hopefully HCC later this year, but What's the next tumor type maybe that's coming out of O2-1 that's going to be really exciting beyond these?
25:37 So we have a number of ions in the fire, so to speak, and ongoing studies. And you mentioned yourself, we have the 312 study in first-line HCC that is ongoing and comparing cabozantinib plus atezolizumab versus serafinib. We have the 313 study and RCC on the backbone of Nebo-Ipi adding in carbazantinib. And certainly a lot of indications going through evaluation in the COSMIC-O2-1 study. We also, one indication you haven't mentioned, I think, is our single-agent evaluation of carbazantinib in a differentiated thyroid cancer.
26:25 We're looking in the for that trial. We've involved 100 patients in February, and we look forward with a sufficient follow-up of a minimum of six months to evaluate the objective response rate in that trial. So lots ongoing, and certainly lots to come as the year rolls on.
26:56 Okay, and last one, Mike, XLO29, can we have any sort of clarity? And I know it's in this year that you're planning on maybe having a first look at that. Any chance we can get a little more clarity on when we'll see that?
27:11 Yeah, why don't we, thanks for the question, why don't we have Peter address that? Peter Lamb, you want to go ahead?
27:17 Yeah, sure. So for XLO29, and actually for a number of our more advanced preclinical programs, We're definitely intending to present data on those in the second half of 2020. As we've kind of guided, we have the opportunity to file up to three INDs this year based on what's going on preclinically right now. As of now, that opportunity is still there, so we look forward to getting some information out on a number of those programs and 092 in the second half, as I said. I haven't quite finalized yet exactly where or what meetings or exactly what the content will be, so stay tuned and we'll update as those details get locked down.
28:02 Great. Thanks a lot, guys. I'll jump back into you. Astitia signing out. Okay. Thanks, Africa. Your next question comes from the line of Yaron Werbern with Cowlings.
28:16 Yeah. Hi. Good afternoon and nice quarter. I have a couple of questions. Maybe actually let's start. I think that 092 is actually critical to the way we kind of look at the business over the long term. And so maybe just a couple of questions. One, have you started the combination cohorts yet that were going to follow the monotherapy data? And then as you think about what you need to establish to move to phase three, is it possible to start a pivotal next year? And then I have a question about CAVO.
28:53 Go ahead.
28:56 Sure. Sure. Thank you, Mike. So regarding your question where we are at on the 092 evaluation, we are in the dose escalation phase still on single agents that are preparing for the evaluation with checkpoint inhibitor combination and that we expect to occur in the next few months. And they're are opportunities to expand cohorts, a little bit like we've done in the COSMIC-021 study, involving larger numbers of patients in certain indications. And if we like what we see there, we could potentially move forward relatively quickly from such observations, but it all will be data-dependent.
29:50 Okay, and maybe, Gisela, for ASCO, in COSMIC-021, the data in lung cancer and second line, can you give us a sense, how many patients in combination with the centric should we see? I recall it was expanded up to 80 patients. And then how do you look at what's the right bar to move to a pivotal on both OR and let's say durability of response?
30:18 Yeah, you know, like we said in prior calls, we want to see sufficient follow-up in the cohorts, and so that's what we've been aiming for for all our presentations and continue to do so. We'll have the first look at that at ASCO for the lung cancer cohort and checkpoint inhibitor pretreated patients. Excuse me. and certainly look forward to that first evaluation. And as you said, we've already begun to expand that cohort further. So I won't get into specific patient numbers. We'll see that shortly at ASCO. And regarding your question on the bar, there's certainly data out there on single agent approaches in the setting or combination approaches and While we don't want to speculate on numbers at this point, I think we certainly look forward to presenting the data at ASCO and showing you the results at that point in time.
31:23 Okay. But you're thinking that if we look at the combination of docetaxel and Rumi, that kind of response rate in the 20s is the right bogey? You're not thinking that docetaxel single-agent response rate of, let's say, 16 or 20? or 6 to 16 at the bogey.
31:45 Yeah, as I said, there are multiple data points out there and certainly in the literature and you mentioned a couple and so I'll leave it right there.
31:55 Okay. Chris, maybe just a quick question just to make sure we heard you and it's my last question. Did inventories increase to 2.9 weeks from 2.6 weeks and it remained within the normal range? I missed exactly the comments on the growth that you mentioned in inventories. Thank you.
32:10 Yes. Yeah, you're honest, Chris. So inventory did increase by about 500 units, which increased our weeks on hand from Q4, which is 2.6 weeks, to 2.9 weeks as we ended Q1.
32:24 Thank you. Thanks, Jeroen. Your next question comes from the line of Andy Shea with William Blair.
32:33 Oh, great. Thanks for taking my questions, and I hope everyone at X elections is well, staying safe and healthy. I want to congratulate on the team for the positive and competitive 90-hour results. So related to that, you know, I think both the physician and investment communities are trying to do cross-track comparisons and totally understand patient and overall survival. But curious about your thoughts on progression-free survival. in the context of a head-to-head comparison. Perhaps that's a clear and maybe less confounded efficacy metric. Curious about your thoughts there.
33:15 Yeah, thanks, Andy. Gisela, why don't you start there, and then maybe PJ can provide some color commentary, too.
33:23 Absolutely. So, first of all, we're really pleased, of course, that the study met all three efficacy endpoints. and showed such strong and consistent results. Regarding PFS, it's the primary endpoint evaluated by independent radiology review. It is unconfounded, of course, by subsequent therapy because of the nature of how it is measured. And I think it certainly showed a very strong result, but so did the other endpoints as well. With that, I'll hand it on to PJ.
34:06 Yeah. Hi, India. I hope you're doing well, too. You know, based on the market research we've done in 9ER, you know, first of all, we're extremely excited by the results, the top-line results we have out there. Look forward to presenting it. You know, it's really the totality of the data we've seen historically in terms of the efficacy is all important, you know, depending on the patient. etc. So we're pleased to have all these endpoints be positive with the strength they have. And importantly, too, I think, in this, as we've mentioned, the tolerability profile is important as well. We hear that from physicians and are pleased with that as well from 9ER. And that's certainly important to be able to get the patients on therapy and then appropriately manage them and keep them on therapy for a long time, which is why we're excited about the results. This should be very important for the patients themselves and then really for the Cabo businesses.
35:04 We look to increase market share in the first-line setting and ultimately the duration there as well.
35:12 Okay, great. Thanks for that additional insight. So at AACR, we saw the detailed results in the Ambassador 250 trial. So, you know, things, these were sort of providing sort of and the pre-clinical rationale of the potential synergy between CAVO and checkpoint inhibitors. You know, I'm just wondering about, you know, any, you know, additional thoughts to put the cohort six in context given, you know, what has transpired at AACR.
35:45 Yeah, I think what was certainly interesting is for us and our cohort six data is that we saw a strong response rate per resist per the design of the trial. It was a 32% objective response rate in a situation where neither cavizantinib nor atezolizumab resulted high response rates by themselves. In fact, they're and partly any responses observed and published in this setting. So that, I think, signals to us a cooperative activity and certainly we have the basis on the biological front that cobizantinib results in a more immune permissive environment enabling the checkpoint inhibitor activity. So I think that's I think the data that we can speak to Ambassador was a negative study and didn't show any improvement over enzalutamide alone in the combination and that in a large study and so that's a definitive answer I guess for this particular setting and that combination
37:18 but I think we need to look at each combination and the biological rationale thereof independently.
37:27 Okay, thanks. And two quick ones. Just an interesting observation. I think if you look at the Keynote 426 study, it's a Merck-sponsored trial, Javelin, Riemel 101, that's a Pfizer-sponsored trial. So the data for both trials were not included in the DUNYDA label. So I'm just wondering, You can educate us on kind of the labeling process on the regulatory side, given the fact that, you know, Bristol is kind of driving the process. And also, in terms of the bench trial, thanks for the additional information in the 10-K, April 2022 start date, I just want to make sure that, you know, if this goes all the way to the appeal process, During that time, is the patent still enforceable?
38:24 Okay, Gisela, why don't you go ahead and take the regulatory question first, and then I'll come back to the last question.
38:33 Sure. So, regarding the inclusion of data in the label for a specific compound that is of course the decision of each company to amend the label and as we stated in the past we're working collaboratively with BMS to work expeditiously towards a regulatory filing and we would anticipate that of course to be led by BMS who was the sponsor for the study of Checkmate 9-ER, but we would also anticipate a more or less parallel filing to the Cabozantinib label. So it's ultimately a decision of the sponsor, really.
39:25 Got it. Thank you.
39:29 Andy, it's Mike. And your last question, obviously all the patents in the Orange Book are enforceable.
39:39 Okay, great. Thanks for answering all my questions. Thank you. And your next question comes from the line of Peter Lawson with Barclays.
39:51 Hi. Thanks for taking my questions. On the 90-hour data, congratulations, but then on top of that, are you seeing any off-label use by physicians after After hearing about the top-line data, have you seen that uptick? And I've got a follow-up after that.
40:12 Yeah. Hi, Peter. It's PJ. First and foremost, we obviously don't promote any off-label data. And I will say, you know, it's very early in the data not having been presented, you know, I think generally, in general terms, one wouldn't expect any of that. At this point, I mean, I think what we're pleased by, what I mentioned in my prepared remarks in terms of Q1 is really the strength in the business in terms of being stable in the first-line RCC new patient market share from the monotherapy perspective and then certainly very pleased with growth in our second-line new patient share now reaching 45%. So I'm very pleased with that momentum in the current business as well as the excitement in preparing for 9ER.
41:00 Thank you. And then I guess kind of a follow-up around COVID. You've seen any increased carbon use amid social distancing and any way of breaking that out? And do you think if you are seeing that benefit, does that stay?
41:18 Yeah, Peter, thanks for the question. Yeah, we haven't seen any incremental use from that perspective. You know, it certainly occurred at the shutdown at the end of Q1. Just really pleased our team is doing everything they can to support our customers who treat the patients who are on Cop-O-Medix, and I think doing that appropriately. We have a lot of digital tactics in place. Generally, we're doing more of those. We've been able to convert a lot of our in-person meetings, communications, speaker programs to virtual, either telephone or online meetings, which is great, doing that compliantly. and, you know, like I said, I think the strength we're seeing in the business is really related to the increase in second-line market share.
42:08 Great. Thank you so much. Thanks for taking the questions. Thanks, Peter. And your next question comes from the line of Michael Smith with Guggenheim.
42:20 Hey guys, thanks for taking my questions and congrats on the quarter and the checkmate data as well from me. Maybe just a follow-up for PJ. What market share does Enlighta, Keytruda combination now have in the frontline RCC setting and how do you think about potentially overcoming any kind of potential inertia by physicians to switch over either from that or from over to Cabo Optivo pending approval of that label.
42:57 Yeah. Hi, Michael. Thanks for the question. So what I mentioned in the prepared remarks and what we've said previously is that the ICI combinations have really stabilized, and that's going back to the end of last year in terms of their market share, new patient market share in the first line, somewhere around the 75% range altogether. And I think, you know, approximately you could think of Pembro, AXI, NEVO would be approximately each having half of that. So I think when we look forward at the 90-yard launch, we're certainly really excited and the data will be very important. So we're pleased that we have good data and look forward to presenting that. The other thing I think about is our team has a lot of experience now in this market in RCC.
43:44 We've now been approved in RCC for just over four years. and have a stable team in place in that time with a lot of depth of knowledge and relationships, frankly, in the marketplace. So I think that's a great thing. And then as you look at the two drugs we're talking about here, as we said previously, Cabo Medix, Opdivo were really the first and only monotherapies to show an overall survival benefit in RCC, which certainly gave us optimism in terms of the trial results. So we're really excited to work with that and build on that as we move forward for the launch.
44:24 Great, thanks. And then just on COSMIC 021, I know that you and Roche have committed to a Phase III trial for some time now in non-smart cell lung cancer. and I was just wondering if there's still an opportunity to maybe consider an accelerated approval pathway in this indication like you have done in prostate cancer or if this is, you know, if this is certainly to go into a fully-fledged randomized phase three trial at this point.
45:05 I think, you know, obviously we want to see the data at ASCO. And as you know, we have expanded as a cohort to a total of 80 patients to be involved in the COSMIC-021 study. And any such considerations would be entirely data-driven. That said, we are moving forward jointly with our collaborators at Roche on the program across these three phase three studies in lung cancer, prostate cancer, and also RCC and look forward to starting those studies in the next few months.
45:48 Okay, thanks. And maybe just one more, Gisela, with regards to the cohort six prostate cancer arm of the study. How should we think about potentially updating that cohort down the road at a medical conference before potentially filing SHIPA data on that in the process?
46:16 Sure. I think right now it's a little bit too early to say because, of course, we will want to see sufficient follow-up also for the expounded cohorts, but we would anticipate certainly presenting the data once mature and whether or not that coincides or comes before any regulatory steps if warranted by the data that really remains to be seen. It's a little bit hard to tell right now.
46:49 Okay, great. Well, thank you for taking my questions.
46:52 Thank you, Michael. Your next question comes from the line of Jason Gerberry with Bank of America.
47:00 Hey, good evening. Thanks for taking my questions. A couple for me. So just first in renal cancer, one of the things that we're hearing from physicians is that use of Updivo Urovoi is coming under pressure because patients who might get this are in a high-risk age demographic. The Urovoi-related immune toxicities are a concern. So I'm wondering about how you see that as potential opportunities, the Checkmate 90-R opportunities eventually rolled out into the market because the obvious beneficiaries would be TKI mono or an IO TKI combination. So first, I guess I'll just leave that there just to get your guys' thoughts on that question.
47:40 Yeah. Hi, Jason. It's PJ. You know, I think with regards to the data we've seen in the market thus far in terms of market data, sort of commercial data, we haven't seen, as I kind of mentioned previously, a big impact to COVID one way or the other. We're pleased that the Cabo business is strong and that our TKI monotherapy frontline market share is stable. And in particular, it's growing in the second line as more patients just really in the kinetics over time are progressing off of immune checkpoint inhibitor therapies. And we're capturing the vast majority of those in the second line. And we anticipate that strength to continue. But, you know, as far as speculating with regards to COVID-19, So many months out with regards to our launch.
48:28 I wouldn't really want to do that. I think what's really going to be important is the data, and we're really pleased to be able to have the opportunity to bring that to customers.
48:38 Got it. So it sounds like you don't see much of an impact to the Epivo-Urvoi combo in renal. My other question was just on lung. I realize that you guys aren't going to say much about patient enrollment strategy, but from what we see from other companies in the space, It looks like they're requiring patients, some at least, to have been on IO for at least four months, presumably to select for patients who have acquired IO resistance. So I'm just curious to get your thoughts on whether you think that's a prudent enrichment strategy going into this post-IO setting. And in doing so, does that materially reduce the addressable market size? Thanks.
49:19 If you want to take that one?
49:21 Sure, sure. Yeah, I guess the question that you're asking is one of acquired resistance versus a priori resistance. And there's, of course, some debate around the prognostic value in that. And so allowing in patients who have had a minimum of four months or longer of prior checkpoint inhibitive treatment, such as the That might be a quiet, resistant population, and that population might do a little bit better than those who progress right through a checkpoint inhibitor therapy. So I think, of course, we're still learning about this field day by day, and I'm not sure that the enrichment strategy would go towards a if you will, worse patient population if you require longer prior treatment durations on checkpoint inhibitors.
50:28 Got it. And if I could just squeeze one follow-up in, just following Checkmate 9ER, not to go back and forth here, but I did. Are you more optimistic about the IO-IO-CABO triplet in development after Checkmate 90R in terms of either your ability to move the needle from an efficacy perspective or just the safety that you're seeing with the CAVO 40 milligram starting dose and how physicians are better at learning how to dose modify. Thanks.
50:59 I think we're very excited about the triplet most certainly and have been. and the results of CheckMy9ER perhaps if anything further reinforces that because of the opportunity to achieve even more with a three drug strategy. And what has been seen in the early Phase 1B studies done at the NCI was certainly encouraging Regarding the tolerability, I think certainly physicians over the time now that checkpoint inhibitors have been available alongside TKIs have gotten accustomed to treating patients with these combinations and are well-versed in modifying a dose or holding the checkpoint inhibitor in going in with steroids if required.
52:01 So there's a lot of learning that has occurred there as well, which certainly bodes well for the COSMIC 313 study as well.
52:14 Jason, I would also add just one thing to think about in the context of 313. Remember, both in terms of the Checkmate 214 data as well as how we're framing and how we wrote the protocol for 313, IPI is given in four consecutive cycles. And then it's essentially the doublet Cabo Nevo versus standalone Nevo as well. So in this quasi-maintenance phase, you know, we kind of like that dynamic too based upon the 9ER data and potential read-throughs there. So there's many different ways to win in terms of not only a more powerful triplet potentially, in the early part of that dosing, but also then in terms of a long maintenance phase, potentially having combo nevo there available, which we think is encouraging based upon the 90-hour data.
53:10 Got it. Great. Thank you.
53:11 Yep. And your next question comes from the line of Sylvain Perkin with Oppenheimer.
53:20 Hi. Thank you for taking my question, and congrats on the great quarter. My first question is, how would you view the second-line CABO monotherapy use evolve once CABO NEVO is launched and frontline? And basically, is CABO's second-line OS benefit here key for it to continue being the preferred choice of TKI post-failure? And secondly, could you tell us a little bit more about your adjuvant therapy efforts in renal cell carcinoma? Is there a path forward, and what will be the timing here?
53:57 Yeah, hi, Sylvan. Thanks for the question. This is PJ. I'll talk about the second-line dynamic and then perhaps pass it to Gisela to comment on adjuvant. But basically, I think what we've been talking about a while with the second-line dynamic and the growth we're now seeing in terms of new patient share to 45%, that's really taken years to sort of play out with those patient kinetics in terms of, if you think about the timing and approval of Panaxi and Nevo, it'd be over a year. So those patients, many of them are already on therapy, right, on ITI combo therapy, and are going to continue to flow into second line for years to come. With regards to 9ER, obviously, you know, pending regulatory timelines, we'll have the opportunity to get approved in the first line setting and then grow market share and duration there. But I really think at the same time, and you asked an astute question, is that the second line market could continue to grow because of the patient dynamics for some time. So in a sense, it could certainly be a possibility where we're growing in the first line and the second line in RCC, you know, a combination and monotherapy respectively, which really reinforces, you know, the Cabo position with all of our studies and data in RCC and being the TKI of choice both now and moving forward for many years to come.
55:22 Yeah, you know, this is Mike. We've talked about this vision where, based upon the totality of the data, you know, we'd like to be able to see every patient who has renal cancer, you know, be able to benefit from CAVO at some point, you know, in their journey from first line to second line to third line. And I think the way PJ framed it and certainly the powerful data we have with 9ER and the, you know, The body of data we have in the second line really makes that a possibility for us to meet that vision head on. So we have a lot of work to do yet, but certainly that's the direction that we're working towards as we go forward.
56:05 Oh, and then just on the, if you have any plans for adjuvant therapy and what the timing there will be. Yeah, Gisela, you want to address that, please?
56:15 Sure. Yeah, at the current time, we don't have an adjuvant trial ongoing for cabozantinib in RCC. We have, in the context of ISTs, new adjuvant approaches that we're looking at that are going forward eventually. And certainly, we are interested in this space. But it is a long-term proposition, of course. and so there may be some opportunity at some point for 092 to play in that space as well. So stay tuned, I would say.
56:54 Great. Thanks for taking my questions and stay healthy.
56:57 Thank you, Sylvan. You too. Your next question comes from the line of Kina McKay with RBC Capital Markets.
57:06 Hi. Thanks for taking the question. Obviously, there is something special to combo combinations with immune checkpoints. Maybe additive, if not perhaps synergistic benefit there, as was tossed around ASCO-GU back in what feels like a former life when in-person meetings were happening.
57:25 I'd love to get your current thoughts around this.
57:28 Is this additive or really sort of potentially synergistic, especially as we think about prostate cancer, where atezolizumab on its own didn't See, really, any responses to speak of and has since been discontinued as a monotherapy. And then two quick follow-ups on lung cancer as well.
57:48 Yeah, thanks for the question. You know, we banter about, you know, the S-word synergy all the time. Maybe Peter could speak to that briefly at a high level. Peter, you want to?
58:01 Yeah, I mean, I think what I'll do is essentially just reiterate why we're excited from a scientific perspective. You know, rationale point of view about cabizantin combinations with checkpoint inhibitors and, you know, why this has been leading to the clinical data that we're starting to see. I mean, obviously it comes down to the cabizantin target profile and the impact that it has on the tumor microenvironment. If you look at, you know, MET, AXL, you know, VEGFR, they play important roles in the regulation of a variety of immune cell subsets, and that includes activation of CD8 positive T cells, and we also have some data showing activation of NK cells, as well as inhibition of a variety of immunosuppressive cells like Tregs and MDSCs, which we've seen, at least peripherally, in a number of clinical trials and certainly preclinically. So I think it's that totality of that profile where we have impacts directly on the tumor, we have impacts on both the adaptive and innate immune system that's really feeding into the clinical data that's emerging and most strikingly in the 9ER data.
59:08 And then maybe the follow-ups on lung cancer. Obviously saw the COSMIC 021 lung title at ASCO. Again, just hoping to maybe understand a little bit what you see as sort of the clinical bar for these patients or similar patients. Were they to get standard of care chemotherapy? And then similarly, I'm hoping to understand a little bit how you are thinking about the patient population of contact 01. Is that sort of going to be the same as this expansion of COSMIC-021 or maybe considering a different subpopulation of the non-small cell lung cancer space?
59:50 Sure. Well, as we discussed a little bit earlier on, there are a number of benchmarks out there. and, you know, you mentioned chemotherapy or chemotherapy plus Ramaziramab or other combinations. And in general, I think the benchmark is sort of in the framework of between 10% and 20% or something in that response rate. and it's not a particularly long-lived response. But I think, you know, of course, you can look at all these data points yourselves and make up your mind there.
1:00:37 Regarding the patient population that we're looking at in O21, we're requiring for patients to have received checkpoint inhibitors prior, the lone or in combination. or subsequent to chemotherapy and in broad brush strokes. It will be a similar patient population in the context of two specifics will certainly appear on clinical trials when ready. And so I won't steal the thunder here and let that be rolled out when the time comes. Thank you. Your next question comes from the line of Stephen Woolley with Stiefel.
1:01:34 Yeah, good afternoon. Thanks for taking the questions. And I hopped on a little late, so my apologies if I'm repeating anything here. But just with respect to contact O2, the phase 3, and prostate, can you maybe just talk about when we might get a little bit of insight into what trial design looks like there. And I think you were asked an ambassador question previously. And, you know, just curious as to how you're thinking about the selection of a control arm at this point. Presumably you could opt for, you know, a novel hormonal like Enza that hasn't been used previously. You probably have salvage chemo as an option as well and Just wondering, you know, if you can just kind of walk us through a little bit how you're thinking about control arm selection, and then specifically if there's anything within that ENSA control arm that kind of, you know, piques your interest with respect to perhaps selecting it.
1:02:39 Yes, so, excuse me, in terms of the Signal that we're building on, of course, it's what has been seen in ASCO-GU with a strong response rate for the COVID-6 with 32% and generally consistent effect on PSA responses and a good durability of response. So that's what we're building on in this patient population. as we're thinking about the phase three trial. And there's a variety, as you mentioned, of opportunities, possibilities regarding control arms. Certainly, NOVA and HT is amongst them. And it is a choice that many prostate cancer patients value because it would potentially allow them I do feel of chemotherapeutic opportunities or options.
1:03:45 So that's certainly a consideration that we're taking into account when the study will roll out. And I think we're working on it hard and anticipating it moving forward and rolling forward and being able to speak about it in more detail over the summer.
1:04:14 Okay. That makes sense. And I guess I agree with your insinuation that ENSA-R would probably make for easier enrollment. And then maybe just one quick one for PJ. Any change just in general prescribing patterns, I guess, specifically with respect to maybe the number of patients who are getting a script filled greater than 30 days, or has that remained relatively stable?
1:04:40 Yeah, I think, you know, as we mentioned before, we're seeing strength in the business, particularly in terms of the second line. New patient share growth, but generally, you know, other metrics – are remaining relatively consistent with what we've seen. We're certainly pleased with the team there doing everything they can sort of normally and now in terms of helping patients and our customers with ExoLixis access services. So we're continuing to see patients get drugged efficiently and certainly gratified by that.
1:05:14 Great. Thanks for taking my questions. And congrats on 9ER. Thank you. Your next question comes from the line of George Farmer with BMO Capital Medicine.
1:05:28 Hi, good afternoon. Thanks for taking my questions. I hope everyone is well over there. I'd like to ask about this backlog that you had talked about at the end of the last year with patients that seemed to be staying on frontline therapy longer and that may have contributed to cable medic sales weakness. Do you think we're through that? And then if so, why not revise guidance given the relatively strong quarter that you just had? And I have a follow-up.
1:06:05 Yeah. Hi, George. This is PJ. You know, I think we have talked about that trend, right, in terms of second-line patients for coblometics being, you know, coming after an ICI combination in the first line. and we saw that sort of stabilize in terms of those kinetics in the latter part of last year and we really have now seen growth in terms of the number of ICI pre-treated patients coming into the second line now where CaboMedix really captures the majority of those patients where we have really the only overall survival benefit is a monotherapy TKI in that setting. and, you know, we would anticipate that trend given the timing of those sort of patient flow kinetics continuing, frankly, and I think we're just sort of starting to see the beginning of that in terms of the strength of the second line.
1:07:02 And George's, Chris, so on the guidance question. It's early in the year. As PJ talked about, we had strong second-line demand, and that continues to grow. We also had the inventory build in the quarter. If you back that out, that would reduce the annualized number. Overall, I'd say we're squarely in the middle of the guidance range. and that guidance also doesn't include 9ER. There's a lot of moving pieces, particularly around the COVID-19 and the pandemic. We're comfortable with where we are right now.
1:07:45 Okay. And then regarding CONTACT-03, this is your Phase 3 trial with Roche in RCC looking at a TEZO with CABO. I noticed on clinicaltrials.gov that the and many others. So I think it's important for us to think about what is the right comparator, is CABO alone? Given how this whole field is evolving and it's getting kind of crowded, certainly in the frontline setting, do you think CABO is the right comparator in this trial and is this trial going to be sufficient for regulatory approval?
1:08:26 A standard of care in the second and later line setting and the treatment paradigm of RCC, and I think that's what this study is building on, evaluating atycilizumab addition on the backbone of cabozantinib. So yeah, I do think it's an appropriate comparative, absolutely. And the study is being designed, has been designed It's being sponsored by Genentech, Roche, and certainly Genso with registrational intent.
1:09:07 Great. Thanks very much.
1:09:09 Okay. Thank you, George. Your next question comes from the line of Paul Choi with Goldman Sachs.
1:09:19 Good afternoon, everyone, and thanks for taking our questions. My first question is on COSMIC 312, and just given the robustness of the data you saw earlier with Checkmate 040, can you maybe just remind us that, you know, if there is an interim built into the trial, an interim look built in this year, and if that's something that we could possibly see in the back half of the year ahead of the primary completion, or is the plan to see the trial all the way through to the final result. And then I have a follow-up question on one.
1:09:58 Yeah, regarding COSMIC 312, this is an event-driven analysis strategy that underlies the design of the study. And there's the interim analysis for overall survival at the same time as the primary analysis for progression-free survival and many others. So, in terms of the timing, it really is entirely dependent on events and the monitoring events will certainly be prepared when The event count is getting closer.
1:10:55 Okay. Thank you for that. And then on the topic of lung, you and your partner, Bristol, have had a trial listed on clinicaltrials.gov, Checkmate 79X for a while, which involves a triple combination of nivolumab, ipilimumab, and cabozantinib. and maybe just comment on whether the plan is still to kick the trial off this year. And then, you know, if the triple accommodation there, you know, proves to have some response, you know, how would you potentially frame that against your ongoing plans for the CONTACT-01 trial, the phase three trial that you're planning in the second line long indication? Thank you very much for taking our questions.
1:11:44 Sure, regarding the study 79XLX, this is a trial sponsored by BMS, and the expectation is that that study is kicking off as we speak. And as you said, it's on clinicaltrials.gov, it's listed there. And regarding the second question, everything is data dependent, but certainly we are moving forward towards initiation, and that is in both stands for off-contact O2. And we'll see the first look at the cohort 7 from the Cosmic O21 study at ASCO. So everything is marching forward sort of in parallel at this point.
1:12:36 Okay, thank you for that. and your final question comes from the line of Jeff Hung with Morgan Stanley.
1:12:47 Thanks for taking the questions and congrats on 9ER. Can you talk about your commercial field team's experiences with virtual touchpoints and if there have been any changes they've observed with healthcare professionals on metrics such as frequency of interactions and has this improved in recent weeks? I appreciate anything anecdotal you can share and then I have a follow-up.
1:13:06 Yeah. Hi, Jeff. This is PJ. I guess what I'll say about that is we're certainly pleased with the efforts of the team in supporting the healthcare providers and the patients appropriately and compliantly. With regards to what we've seen, we have a pretty experienced team, and we feel we have a good sort of yield or conversion from in-person touch points to virtual ones. And I think a lot of that is because of the experience of the team and the fact that this team has been in place and many secondary research, albeit small ends, where we've converted more in-person calls to virtual the most, I should say, in the RCC market.
1:13:52 But, you know, it's early. It's really a local-by-local basis, and things are obviously dynamic, as we're seeing, and we're planning on, you know, doing everything we can to appropriately support our customers and our patients while maintaining and obviously vigilance on the health of our employees and all of them as well.
1:14:14 Great. And then with substantial safety stock inventories for commercial drug substance and drug products that are sufficient to maintain supply for a long period of time, can you talk about what kinds of levers you have and what kinds of manufacturing modifications you can make if COVID continues for longer than expected? Thanks.
1:14:33 Yeah, it's Mike.
1:14:34 Yeah, look, we have a very deep, robust supply chain for compost antinode with various stockpiles of intermediates stored at various positions and regions in the process. So we have literally years of stock in hand, ready to go. So we have really got that covered. That's a heads-off to the the CMC and supply team here for really investing in not only the primary supplier but we have a whole secondary supplier supply chain that's now coming online for both drug product and drug substance as well to further augment the growing number of indications that we expect in the coming years but also to further reinforce that supply chain.
1:15:25 So long stability of both API and drug product as well in both the tablet and capsule format. So we've got that covered pretty well. Thanks for the question.
1:15:37 Thanks. At this time, there are no further questions, and so I will turn the call back over to your host today, Ms. Susan Hubbard. Ms. Hubbard?
1:15:52 Great. Thank you, Nita, and thank you all very much for joining us today. We really appreciate your participation on the call, and are standing by to answer any questions that were left unanswered during today's call. Thanks again. Be safe. Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and you have a wonderful day. You may now all disconnect.
Follow Exelixis, Inc. into a list and get an email when it puts out news.
EVP of Public Affairs and Investor Relations
President and CEO
Chief Medical Officer
Chief Financial Officer
Executive Vice President of Commercials
Chief Scientific Officer
Analyst at SunTrust
Analyst at Cowen and Company
Analyst at William Blair
Analyst at Barclays
Analyst at Guggenheim
Analyst at Bank of America
Analyst at Stifel
Analyst at Oppenheimer
Analyst at RBC Capital Markets
Analyst at BMO Capital Markets
Analyst at Goldman Sachs
Analyst at Morgan Stanley